Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02628405 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT02628405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02628405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 20, 2016
Completion date
December 20, 2025
Enrollment
30 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b-cell non-hodgkin lymphoma, recurrent diffuse large b-cell lymphoma, recurrent primary mediastinal (thymic) large b-cell lymphoma, recurrent transformed non-hodgkin lymphoma, refractory b-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory primary mediastinal (thymic) large b-cell lymphoma, refractory transformed non-hodgkin lymphoma